China Resources Pharma unit KPC expects H1 net loss of RMB 400 million to RMB 330 million

• China Resources Pharmaceutical flagged a sharp first-half loss at KPC, a Shanghai-listed subsidiary held via CR Sanjiu at about 29.08%.
• KPC forecast net profit attributable to shareholders of RMB -400 million to RMB -330 million, versus RMB 198.36 million a year earlier.
• KPC forecast net profit excluding non-recurring items of RMB -430 million to RMB -350 million, versus RMB 151.1 million a year earlier.
• The prior-year first-half total profit was RMB 298.94 million; earnings per share were RMB 0.26.
• KPC cited policy tightening, broader centralized procurement, channel optimization, slower shipments, marketing reforms, weaker sell-through, and inventory digestion pressures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260714-12243833), on July 14, 2026, and is solely responsible for the information contained therein.